Table 1.
Compound | Model | Animal species | Dosage | Behaviour involved | Mechanism of action/main indicators | References |
---|---|---|---|---|---|---|
Saikosaponin D | LPS | Male ICR mice | 1 mg/kg | OFT, TST, FST, and SPT | Inhibition of microglia activation, the activity of TLR4/NF-κB pathway HMGB1 translocation, and proinflammatory cytokines ↓ | [16] |
| ||||||
Quercetin | CUMS | Male SD rat | 0.75, 1.5 mg/kg | OFT, TST, and FST, SPT | NF-κB↓, FGF2↑, and miR-155↓ | [18] |
OB | Female SWISS mice | 10, 25, 50 mg/kg | FST, TST, OFT, and ST | LOOH↓ | [20] | |
| ||||||
Kaempferol | CSDS | Male CD1 and C57 mice | 10, 20 mg/kg | SPT, SIT, and TST | SOD↑, MDA↓, CAT↑, GPx↑, GST↑, P-AKT↑, and β-catenin↑ | [21] |
| ||||||
Caffeic acid | LPS | Male Swiss albino mice | 30 mg/kg | OFT, FST, and TST | IL-6↓, MDA↓, GSH↑, and TNF-α↓ | [22] |
| ||||||
Ferulic acid | CORT | Male Swiss mice | 1 mg/kg | TST, OFT, and ST | MDA↓, nitrite↓, and protein carbonylation↓ | [23] |
CUMS | Male ICR mice | 20,40, 80 mg/kg | SPT and TST | IL-1β,I L-6, TNF-α mRNA↓, NF-κB↓ P-NF-κB/NF-κB↓, and inhibition of PFC microglia activation |
[24] | |
| ||||||
Gallic acid | BCCAO | Male balb/c mice | 25, 50 mg/kg | TST and SPT | Antioxidant stress | [25] |
| ||||||
Paeoniflorin | RESP/LSP/ATP | Male C57BL/6 Mice |
10, 20, 40 mg/kg | OFT, TST, and FST | Dendritic spines in hippocampal CA1 region↑, NLRP3↓, CASP-11↓, CASP-1↓, GSDMD↓, IL-1β, and microglia activation ↓ | [28] |
LPS | Male ICR mice | 20, 40, 80 mg/kg | SPT and FST | FGF2↑, IL-6↓, TNF-α↓, TLR4↓, P-NF-κB↓, NLRP3↓, Cox-2↓, and dendritic spine density in CA3 area of hippocampus ↑ | [29] | |
Cuff | SPF male Balb/c mice | 50, 100 mg/kg | SPT, FST, and TST | Inflammation in hippocampal CA3 area ↓, IL-6↓, TNF-α↓, IL-1↓, microglia activation ↓, and TLR4/NF-κB pathway ↓ | [30] | |
IFN-α | Male C57BL/6Jmice | 10, 20, 40 mg/kg | SPT, OFT, TST, and FST | Serum, mPFC, vHi, and amygdala inflammation levels↓ | [31] | |
SLE | Wild type mice and MRL/MpJ-Faslpr/ 2 J (MRL/lpr) mice |
20 mg/kg | SPT, TST, and FST | Activity of HMGB1/TLR4/NF-κB pathway↓, serum, and hippocampus contents of TNF-α, IL-1β, and IL-6↓ | [32] |
Notes: OFT: open field test; TST: tail suspension test; FST: forced swimming test; SPT: sucrose preference test; TLR4: Toll-like receptor 4; NF-κB: nuclear transcription factor-κB; HMGB1: High mobility group box 1; FGF2: fibroblast growth factor 2; LOOH: lipid hydroperoxides; SOD: Superoxide dismutase; MDA: malondialdehyde; CAT: catalase; GST: Glutathione S-transferase; AKT: serine/threonine protein kinase; IL-6: interleukin-6; TNF-α: Tumor necrosis factor-α; NLRP3: nucleotide-binding oligomerization domain-like receptor protein 3; CASP-11: Caspase-11; CASP-1: Caspase-1; GSDMD: Gasdermin D; IL-1β: interleukin-1β; TLR4: Toll-like receptor 4; LPS: lipopolysaccharide; CUMS: chronic unpredictable mild stress; OB: olfactory bulbectomy; CSDS: Chronic social stress defeat; CORT: cortisol; BCCAO: brain ischemia-reperfusion; ATP: adenosine triphosphate; IFN-α: Interferon-α; SLE: Systemic lupus erythematosus.